Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xypex 2025 International Best Project Awards - Winners Announced19.3.2026 21:00:00 CET | Press release
Xypex announces 2025 award winners recognizing excellence in concrete durability, engineering performance, and crystalline waterproofing technology. VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / Xypex announces the winners of the 2025 International Best Project Awards, recognizing construction projects that demonstrate excellence in concrete durability, engineering performance, and the use of crystalline waterproofing technology. This year's program received more than 80 project submissions from over 20 countries across five continents, reflecting the global reach of Xypex technology and the strength of its international network of distributors, engineers, contractors, and partners. The submissions represented a broad range of projects across infrastructure, general construction, water and wastewater facilities, industrial structures, and small-scale applications. Projects were evaluated based on engineering complexity, construction challenges, durability requirements, and the int
Brookville DMAX Expansion Highlights the Project Work Behind a Major Ohio Manufacturing Investment19.3.2026 16:00:00 CET | Press release
BROOKVILLE, OH / ACCESS Newswire / March 19, 2026 / General Motors' Duramax Engine Plant (DMAX) expansion in Brookville has become one of the region's most significant industrial projects, tied to a $920 million investment supporting Duramax diesel engine production for GM heavy-duty truck programs, including Chevrolet Silverado HD and GMC Sierra HD models. Public reporting has described the Brookville work as adding about 1.1 million square feet to the existing facility which was previously approximately 250,000 square feet. Notably, the project has created and supported hundreds of local jobs as the site expands its manufacturing footprint in southwest Ohio. This expansion quadruples the current facility size and is designed to create over 800 jobs, supporting high demand for diesel trucks. Among the professionals helping carry that work forward is Sabra Sadeghi, a project architect and engineer who served on the Brookville expansion in an on-site role. The project has been praised f
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina19.3.2026 12:00:00 CET | Press release
Seasonal and Seaside Styles Debut Alongside U.S. Open Polo Championship Capsule WEST PALM BEACH, FL / ACCESS Newswire / March 19, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has launched its sport-inspired Spring-Summer 2026 Global Collection, a vibrant seasonal lineup inspired by coastal Americana and the relaxed spirit of seaside living. The campaign was photographed in historic Charleston, South Carolina, where Rainbow Row's pastel architecture, coastal landscapes, and the heritage of the Hyde Park Polo Club field create the perfect backdrop for the iconic global brand's latest styles.U.S. Polo Assn. 2026 Spring-Summer Global Collection Photoshoot in Charleston, South Carolina The U.S. Polo Assn. campaign once again highlights the authentic connection between the sport of polo and the globally recognized lifestyle brand inspired by the sport. Apparel and accessories from the Spring-Summer 2026 Global Collection are now available. G
Datavault AI Enters into Definitive Agreement to Acquire NYIAX, Combining AI-Driven Data Monetization with Institutional-Grade Market Infrastructure19.3.2026 11:30:00 CET | Press release
Pending acquisition will integrate NYIAX's blockchain-enabled exchange platform, built on globally recognized financial market technology and jointly owned patents to power next-generation digital marketplaces. PHILADELPHIA, PA / ACCESS Newswire / March 19, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the signing of a Definitive Agreement to acquire NYIAX Inc. ("NYIAX"). The acquisition will bring NYIAX's intellectual property portfolio and blockchain-powered trading platform built on a globally recognized financial market infrastructure platform into Datavault AI's organization. The combined company is expected to make institutional-grade, transparent trading infrastructure available to customers and accelerate the planned commercial launches of specialized exchanges. The transaction builds upon an October 2025 letter of inte
Powerverse and Teltonika Energy Partner to Unlock Intelligent Home Energy & Flexibility19.3.2026 08:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / March 19, 2026 / Powerverse has partnered with Teltonika Energy, part of the Teltonika group, a multinational leader in IoT innovation, to deliver an AI-driven home energy ecosystem that enhances user experience, unlocks flexibility services and drives long-term customer value. Teltonika Energy's hardware is built with reliability, connectivity and performance at its core, and its devices are designed to support the next generation of intelligent home energy systems. "Teltonika Energy is globally recognised for its high-quality, IoT-engineered hardware," said Richard Britton, CEO of Powerverse. "We are thrilled to combine their robust devices with our AI-driven platform to help customers move beyond simple smart control and into active market participation. Together, we are delivering a fully integrated, end-to-end solution that makes it effortless for users to lower costs, reduce their carbon footprint, and unlock the full long-term value of home energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom